Navigation Links
Cranberry Capsule Proven to Cure Bladder Infection
Date:5/3/2012

AMSTERDAM, May 3, 2012 /PRNewswire/ --

Dutch Medical Brands receives first European Class IIa Medical Device Status

Instead of traditional treatment with antibiotics, bladder and urinary tract infections can be cured with cranberry capsules, without known side effects. Dutch company Medical Brands has obtained a Class IIa Medical Device Status for its patented Cranberry-Active capsule, making it the first and only cranberry-based product in Europe which has a proven medical claim.

Together with American company Decas Botanical Synergies (DBS), Medical Brands spent seven years developing the capsule and getting it patented and approved by the proper authorities.

While the claims of other cranberry-based food supplements will be rejected later this year by the European Food and Safety Authority (EFSA), Medical Brands produced studies which clinically showed that the capsule cures bladder infections. Compared to other cranberry products, MB and DBS developed a unique and proprietary formulation which is proven to treat and prevent bladder and urinary tract infections. It's the first capsule that can be freely sold as a medical device on the OTC market in all European countries.

"Bladder- and urinary tract infections (UTIs) are a serious health problem, affecting millions of people each year. Today, antibiotics are the traditional treatment for UTIs but there is a growing global push towards other solutions as resistance to antibiotics continues to rise. Our Cranberry-Active capsules marketing authorization is the culmination of years of planning, development and clinical investigation," says Maikel Hendriks, president of Medical Brands.

His company is specialised in developing medical devices without pharmacologic effects. It provides consumers with solutions for everyday diseases without the side effects most drugs have.

In the Netherlands the capsule is sold as the Bladder Infection Tablet by 'i say', in other countries Medical Brands is still searching for partners to sell the capsule. To inform potential market partners and consumers Medical Brands and DBS will present their Cranberry-Active capsules at the Vitafoods Europe 2012 conference in Geneva, Switzerland, at the Seminar Theater on Tuesday, May 22nd at 2:00 PM.


'/>"/>
SOURCE Medical Brands
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
2. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
3. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
4. Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
7. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
8. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
9. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
10. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... February 8, 2016 ... published by Allied Market Research titled, "World ... Forecasts, 2014-2020", estimates the world synthetic biology market ... and sequencing technology segment would continue to lead ... tools segment, collectively, held around half of the ...
(Date:2/8/2016)... HOUSTON , 8. Februar 2016 /PRNewswire/ ... veröffentlichte heute eine Infografik mit dem Titel ... ganzen Welt), mit der der Krankheit gegenüber ... die dazu ermutigen soll, Medikamentenresistenz bei Epilepsie ... der allgemeinen Diskussion zu machen. Mithilfe der ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... The schedule ... in this country. The AutismOne 2016 Conference, which is being held May 25-29 at ... won’t hear elsewhere about helpful interventions and causes of chronic illness in children. , ...
Breaking Medicine News(10 mins):